Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 23, 2011

Xenome Secures about $6.2M to Advance Peptide-Based Pain Med

  • Xenome has completed a financing of A$8 million (roughly $6.22 million) to support the ongoing development of antipain medication Xen2174. It is a 13-amino acid synthetic peptide.

    Xenome is developing Xen2174 for the management of moderate to severe pain. It has reportedly shown promise as a non-opiate pain therapeutic when administered intrathecally. The compound is a highly selective and non-competitive inhibitor of norepinephrine transporter (NET), a validated target for the management of pain.

    The current financing is intended to help with a Phase II placebo-controlled multicenter trial of Xen2174 in a post bunionectomy surgical patient population. This trial is intended to demonstrate Xen2174's potential to provide improved postoperative pain relief for an extended period following a single intrathecal administration immediately prior to surgery.

    Xenome is focused on the discovery and development of peptide-based therapeutics. Xen2174 is the firm's lead molecule. It also has an anti-inflammatory discovery program in pancreatitis.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »